GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix ...

A single dose of Ixchiq induced a high and sustained immune response in 99.1% of adolescents, according to Valneva.

Announced U.S. FDA authorization of an Expanded Access Policy (EAP) for metastatic breast cancer (MBC) patients. BriaCell Therapeutics Corp. shares T.BCT are trading up $0.05 at $0.70.